42 results about "Chlamydophila Pneumonia" patented technology

A protective immune response against Chlamydial infection is achieved by in vivo administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor. One of the vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The other of the vectors comprises a second nucleotide sequence encoding a 76 kDa protein of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the second nucleotide sequence for expression of the 76 kDa protein in the host. The protection efficiency which is achieved by the immunization procedure is enhanced over that attained with the individual vectors alone.

The invention discloses a respiratory tract infection pathogen nucleic acid combined detection kit. The invention develops a primer and probe combination for detecting various respiratory tract infection pathogens such as novel corona virus, influenza A virus, influenza B virus, respiratory syncytial virus, human parainfluenza virus, adenovirus, mycoplasma pneumoniae and chlamydia pneumoniae by combining a multiple fluorescent quantitative PCR technology and a diversion hybridization gene chip technology. The nucleotide sequences of the primer and probe combination are shown in SEQ ID NO: 1-36in sequence. The respiratory tract infection pathogen nucleic acid combined detection kit is constructed. Synchronous joint detection of eight respiratory tract infection pathogens can be realized, the detection accuracy is good, the specificity is strong, the sensitivity is high, the repeatability is good, false negative and false positive are low, the detection time is short, the cost is low, apatient can be comprehensively detected, the pathogens can be accurately positioned, timely treatment is carried out or corresponding isolation measures are carried out, and the kit has important significance for effectively controlling respiratory tract infection to prevent related infectious infection outbreak.

The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of this invention.

The invention discloses a rapid-recognition gene chip for pathogenic bacteria of pneumonia. The gene chip can detect 15 pathogenic bacteria including streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae, and clinically common and difficult-to-culture pathogenic bacteria are contained. In a preparation process of the gene chip, design, screening and verification of probes are performed by adopting 16S rDNA and a specific gene sequence corresponding to each of the pathogenic bacteria, and types of the bacteria in a to-be-detected sample are identified from levels of genus and species simultaneously and respectively. The gene chip has the advantages that the defect that clinical detection of the pathogenic bacteria of pneumonia is not timely and comprehensive at present is overcome, and one novel detection way is provided for early diagnosis and early treatment of patients with pneumonia.